Sow vaccine to be brought to European market
Oedema disease occurs naturally in post-weaning piglets and is seen after infection with certain strains of E. coli.
CZ Veterinaria and Boehringer Ingelheim Animal Health are collaborating to bring the sow vaccine, Entericolix, to the European market.
Entericolix prevents diarrhoea in piglets caused by E. coli and C. perfringens type C. The companies say it is unique in providing 21 days of immunity.
It also promises to provide protection against the early onset of oedema disease caused by F18 E. coli in piglets up to 28 days of age (seven days after weaning). Oedema disease occurs naturally in post-weaning piglets and is seen after infection with certain strains of E. coli.
CZ Veterinaria developed the vaccine with the support of the Reference Laboratory for E. coli at the University of Santiago de Compostela. It has been registered in 20 European countries.
Boehringer Ingelheim will exclusively market Entericolix through its swine distribution network.
Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.
